AdAlta Ltd (ASX: 1AD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
AdAlta Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
AdAlta Ltd (ASX: 1AD)
Latest News
Consumer Staples & Discretionary Shares
Up 19% in 2024, is it time to buy or sell Coles shares?
ASX Share Market News
AdAlta (ASX:1AD) share price rockets 31% on United States FDA update
1AD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About AdAlta Ltd
AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The company was founded in 2007 and is headquartered in Bundoora, Australia.
1AD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 19 Nov 2026 | $0.00 | $0.00 | 0.00% | 1,039,875 | $0.00 | $0.00 | $0.00 |
| 17 Nov 2026 | $0.00 | $0.00 | 0.00% | 3,829,659 | $0.00 | $0.00 | $0.00 |
| 12 Nov 2026 | $0.00 | $0.00 | 0.00% | 332,396 | $0.00 | $0.00 | $0.00 |
| 11 Nov 2026 | $0.00 | $0.00 | 0.00% | 800,000 | $0.00 | $0.00 | $0.00 |
| 09 Nov 2026 | $0.00 | $0.00 | 0.00% | 2,768,955 | $0.00 | $0.00 | $0.00 |
| 06 Nov 2026 | $0.00 | $0.00 | 0.00% | 2,260,222 | $0.00 | $0.00 | $0.00 |
| 04 Nov 2026 | $0.00 | $0.00 | 0.00% | 4,500,000 | $0.00 | $0.00 | $0.00 |
| 02 Nov 2026 | $0.00 | $0.00 | 0.00% | 131,990 | $0.00 | $0.00 | $0.00 |
| 30 Oct 2026 | $0.00 | $0.00 | 0.00% | 38,151,684 | $0.00 | $0.00 | $0.00 |
| 29 Oct 2026 | $0.00 | $0.00 | 0.00% | 1,675,309 | $0.00 | $0.00 | $0.00 |
| 28 Oct 2026 | $0.00 | $0.00 | 0.00% | 45,016,546 | $0.00 | $0.00 | $0.00 |
| 27 Oct 2026 | $0.00 | $0.00 | 0.00% | 324,080 | $0.00 | $0.00 | $0.00 |
| 22 Oct 2026 | $0.00 | $0.00 | 0.00% | 410,647 | $0.00 | $0.00 | $0.00 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 04 Dec 2025 | Timothy Oldham | Buy | 1,396,999 | $4,889 |
Conversion of securities.
|
| 04 Dec 2025 | Timothy Oldham | Exercise | 1,396,999 | $4,889 |
Conversion of securities.
|
| 26 Nov 2025 | Timothy Oldham | Expiry | 4,929,060 | $17,251 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Paul MacLeman | Non-Executive ChairmanNon-Executive Director | Oct 2019 |
Dr MacLeman has 25 years' experience in the life sciences sector a career in veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance. Dr MacLeman is also an advisor
to PharmaVentures plc. (Oxford, UK) and serves on NFP and government advisory groups. |
| Dr Timothy Oldham | Managing DirectorChief Executive Officer | Oct 2019 |
Dr Oldham has 20 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia.
|
| Mr Fadi Diab | Non-Executive Director | Mar 2026 |
Mr Diab has 10 years' experience in financial institutions. Mr Diab has experience in corporate governance, strategy, capital markets, mergers and acquisitions companies across the mining, biotechnology and technology sectors.
|
| Ms Michelle Burke | Non-Executive Director | Nov 2024 |
Ms Burke has 25 years' experience in the life sciences sector, with knowledge in pharma and biotech industries. Ms Burke worked at Bristol-Myers Squibb and SmithKline Beecham. Ms Burke is the industry nominee to the Pharmaceutical Benefits Advisory Committee. Ms Burke serves as an advisor for Proto Axiom Pty Ltd.
|
| Mr Cameron Jones | Chief Financial OfficerCompany Secretary | May 2017 |
-
|
| Cameron Jones | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Meurs Group | 293,480,026 | 9.14% |
| Sufian Ahmad | 287,133,321 | 8.94% |
| Mr David Dominic Pevcic | 230,595,264 | 7.18% |
| Sacavic Pty Ltd <Sacavic A/C> | 191,108,388 | 5.95% |
| Ms Chunyan Niu | 181,969,001 | 5.67% |
| Kobala Investments Pty Ltd <Fernando Edward Family A/C> | 124,000,000 | 3.86% |
| Hsbc Custody Nominees (Australia) Limited A/C 2 | 79,574,880 | 2.48% |
| Scintilla Strategic Investments Limited | 75,000,000 | 2.33% |
| Mr Bin Liu | 65,000,000 | 2.02% |
| Mrs Ifrah Nishat | 62,500,000 | 1.95% |
| Dr Michel Elkhoury | 62,161,295 | 1.94% |
| Mr Bilal Ahmad | 52,333,333 | 1.63% |
| Mr Dean Brett Blankfield | 49,166,667 | 1.53% |
| BNP Paribas Nominees Pty Ltd | 39,453,727 | 1.23% |
| Libert Pty Ltd <N & L Muller S/F A/C> | 39,166,667 | 1.22% |
| Mrs Shaista Zaffar | 37,516,667 | 1.17% |
| Mr Joshua Gordon | 31,894,921 | 0.99% |
| CTH Govt Dept SCI IND | 27,029,924 | 0.84% |
| Mr Muhammad Salman & Mrs Sajida Akram & Miss Fatima Salman <Kulovall Family S/F A/C> | 25,000,000 | 0.78% |
| Mrs Gwen Murray Pfleger <Pfleger Family A/C> | 25,000,000 | 0.78% |
| Ponce Pty Ltd <Wexford Arms A/C> | 25,000,000 | 0.78% |
| Agha Family Investments Pty Ltd <Agha Family A/C> | 23,333,333 | 0.73% |